HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism.

AbstractOBJECTIVE:
To investigate the role of T cell induction of matrix metalloproteinase 13 (MMP-13) production by human osteoblasts in order to better understand the process of bone loss in rheumatoid arthritis (RA).
METHODS:
Activated T cell-conditioned medium (ACTTCM) was used to mimic the physiologic conditions of inflammation. MMP-13 production by human osteoblasts was assessed using a specific enzyme-linked immunosorbent assay. Specific inhibitors of the p38 mitogen-activated protein (MAP) kinase and the extracellular signal-regulated kinase 1/2 (ERK-1/2) MAP kinase signaling pathways were used to assess their roles in T cell-mediated MMP-13 production. Finally, recombinant cytokines representative of the major components in ACTTCM were assessed for their ability to induce MMP-13.
RESULTS:
ACTTCM powerfully induced MMP-13 in human osteoblasts. Inhibition of p38 activity abolished, while inhibition of ERK-1/2 activity enhanced, MMP-13 production. We next investigated physiologic levels of the T cell cytokines tumor necrosis factor alpha (TNFalpha), transforming growth factor beta (TGFbeta), interferon-gamma (IFNgamma), and interleukin-17 (IL-17) for their roles in MMP-13 induction. Although individual cytokines had no significant effect, the combination of TNFalpha, TGFbeta, IFNgamma, and IL-17 resulted in a dramatic p38-dependent induction of MMP-13 identical to that produced by ACTTCM.
CONCLUSION:
These studies demonstrate for the first time that human osteoblasts produce MMP-13. The results also show that under conditions of chronic inflammation, multiple T cell cytokines synergize to induce high levels of MMP-13 via a mechanism that is dependent on activated p38 MAP kinase and is suppressed by activated ERK-1/2. Selective inhibition of p38 activity may offer a target for pharmacologic inhibition of bone loss in RA.
AuthorsLeonard Rifas, Sophia Arackal
JournalArthritis and rheumatism (Arthritis Rheum) Vol. 48 Issue 4 Pg. 993-1001 (Apr 2003) ISSN: 0004-3591 [Print] United States
PMID12687541 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Culture Media, Conditioned
  • Cytokines
  • Drug Combinations
  • Enzyme Inhibitors
  • Flavonoids
  • Imidazoles
  • Pyridines
  • Recombinant Proteins
  • SB 203580
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • Collagenases
  • MMP13 protein, human
  • Matrix Metalloproteinase 13
  • Mmp13 protein, mouse
Topics
  • Animals
  • Cells, Cultured
  • Collagenases (biosynthesis)
  • Culture Media, Conditioned (pharmacology)
  • Cytokines (metabolism, pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Drug Synergism
  • Enzyme Inhibitors (pharmacology)
  • Enzyme-Linked Immunosorbent Assay
  • Flavonoids (pharmacology)
  • Humans
  • Imidazoles (pharmacology)
  • Matrix Metalloproteinase 13
  • Mice
  • Mitogen-Activated Protein Kinase 1 (antagonists & inhibitors, metabolism)
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases (antagonists & inhibitors, metabolism)
  • Osteoblasts (drug effects, enzymology)
  • Pyridines (pharmacology)
  • Recombinant Proteins (pharmacology)
  • T-Lymphocytes (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: